Methods of using (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid
(1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).
1. A method of reducing collateral damage selected from the group consisting of visual field defects and intramyelinic edema associated with the administration of the gamma-amino butyric acid (GABA) aminotransferase inhibitor vigabatrin to a patient in need thereof, comprising the administration of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or a salt thereof; wherein the amount administered is from 0.05 to 2.5 mg/kg/day or from about 3.5 to about 175 mg/day for an average adult.
2. The method of claim 1 wherein the patient is addicted to a drug and wherein the (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid limits dopamine increase after administration of a dopamine agonist to less than about 300% of baseline dopamine levels prior to a challenge with a drug of addiction.
3. The method of claim 2 wherein the amount of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid is from about 1/100 to about 1/700 the dose of vigabatrin.
4. The method of claim 2 wherein the drug is selected from at least one of the following: cocaine, nicotine, methamphetamine, morphine, heroin, ethanol, phencyclidine(PCP), or methylenedioxymethamphetamine.
5. The method of claim 2 wherein the dopamine levels are reduced more than 50% in comparison to an untreated subject.
6. The method of claim 1 wherein the patient suffers from a neurological or psychological disorder.
7. The method of claim 6 wherein the neurological disorder is selected from epilepsy, fibromyalgia, neuropathic pain, migraine related to epilepsy, restless leg syndrome and post traumatic stress disorder addiction, obesity, obsessive-compulsive disorders and Alzheimer's disease.
8. The method of claim 6 wherein the patient suffers from a psychological disorder selected from one or more of the following: general anxiety disorder, pathological or compulsive gambling disorder, compulsive eating, body dysmorphic disorder, hypochondriasis, pathologic grooming conditions, kleptomania, pyromania, attention deficit hyperactivity disorder and impulse control disorders.
9. The method of claim 1 wherein the amount of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid is from about 1/100 to about 1/700 the dose of vigabatrin.
10. The method of claim 1 wherein addictive liability is reduced in a patient taking an addictive agent by co-administering (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid along with the addictive agent.
11. The method of claim 10 , where the (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid is administered prior to, concurrently with of after administration of the addictive agent.
12. The method of claim 1 wherein the dose of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or a salt thereof is 2 to 2.5 mg/kg/day for treatment of epilepsy or about 140-175 mg/day for an average 70 kg adult.
13. The method of claim 1 wherein the dose of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or a salt thereof is 0.05 to 0.2 mg/kg/day, or about 3.0-15 mg/day for the average 70 kg adult.
14. A method of reducing collateral damage selected from the group consisting of visual field defects and intramyelinic edema associated with the administration of the gamma-amino butyric acid (GABA) aminotransferase inhibitor vigabatrin to a patient in need thereof, comprising the administration of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or a salt thereof; wherein the amount administered is from 0.05 to 2.5 mg/kg/day or from about 3.5 to about 175 mg/day for an average adult; wherein the (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid inactivates GABA aminotransferase through a di-fluoromethylene intermediate instead of 4-oxohex-5-enoic acid.
15. The method of claim 1 wherein the patient suffers from epilepsy.
16. The method of claim 15 wherein the amount of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid is from about 1/100 to about 1/700 the dose of vigabatrin.
17. The method of claim 14 wherein the dose of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or a salt thereof is 2 to 2.5 mg/kg/day for treatment of epilepsy or about 140-175 mg/day for an average 70 kg adult.
18. The method of claim 14 wherein the dose of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or a salt thereof is 0.05 to 0.2 mg/kg/day, or about 3.0-15 mg/day for the average 70 kg adult.
19. A method of reducing collateral damage selected from the group consisting of visual field defects and intramyelinic edema associated with the administration of the gamma-amino butyric acid (GABA) aminotransferase inhibitor vigabatrin to a patient in need thereof, comprising the administration of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or a salt thereof; wherein the amount administered is from 0.05 to 2.5 mg/kg/day or from about 3.5 to about 175 mg/day for an average adult; wherein GABA aminotransferase is inhibited without preventing reuptake of GABA.
20. The method of claim 19 wherein the dose of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or a salt thereof is 2 to 2.5 mg/kg/day for treatment of epilepsy or about 140-175 mg/day for an average 70 kg adult.
21. The method of claim 19 wherein the dose of (1 S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid or a salt thereof is 0.05 to 0.2 mg/kg/day, or about 3.0-15 mg/day for the average 70 kg adult.